Molecular Partners AG to Present at TD Cowen and | U.S. Markets

Molecular Companions will current at TD Cowen and Leerink healthcare conferences and host a financial outcomes call on March 7.

Quiver AI Abstract

Molecular Companions AG, a clinical-stage biotech company targeted on developing DARPin therapeutics, introduced its participation in upcoming investor conferences and a convention call to debate its 2024 financial outcomes. Key occasions embody a hearth chat that includes CEO Patrick Amstutz and CMO Dr. Philippe Legenne on the TD Cowen forty fourth Annual Well being Care Convention in Boston on March 3 and one other chat on the Leerink Companions International Healthcare Convention in Miami on March 10. The company will host a call on March 7 to debate its full-year financial outcomes, with its Annual Report set for release on March 6. Molecular Companions goals to leverage its revolutionary therapies in oncology and has a number of development applications underway.

Potential Positives

• Participation in vital healthcare conferences enhances the company’s visibility and potential investor curiosity.
• The scheduled convention call for the 2024 financial outcomes supplies transparency and engagement with stakeholders.
• Highlighting the company’s distinctive DARPin therapeutics positions Molecular Companions as an revolutionary participant within the biotech industry.

Potential Negatives

• Presence at a number of investor conferences could point out a need for elevated visibility or confidence from traders, suggesting potential considerations about ongoing financial efficiency.
• The cautionary observe concerning forward-looking statements highlights vital uncertainties and dangers that would adversely have an effect on the company’s future efficiency, which may create investor apprehension.
• Pending outcomes from medical trials and the emphasis on potential dangers may point out challenges in product development, raising considerations about timelines and effectiveness of their drug candidates.

FAQ

What’s Molecular Companions AG?

Molecular Companions AG is a clinical-stage biotech company targeted on developing custom-built protein medicine often called DARPin therapeutics.

When will the financial outcomes for 2024 be introduced?

The financial outcomes for 2024 will likely be introduced on March 7, 2025, at 8.00 am ET (2.00 pm CET).

Who will likely be attending the TD Cowen convention?

Molecular Companions CEO Patrick Amstutz and CMO Dr. Philippe Legenne will take part within the TD Cowen convention hearth chat.

How can I be part of the financial outcomes convention call?

You’ll be able to be part of the call by dialing 1-844-763-8274 (toll-free) roughly 10 minutes earlier than the beginning.

The place can I discover more details about Molecular Companions?

Extra data will be discovered on their web site at www.molecularpartners.com and on their LinkedIn and Twitter/X accounts.

Disclaimer: That is an AI-generated abstract of a press release distributed by GlobeNewswire. The model used to summarize this release could make errors. See the complete release right here.

$MOLN Hedge Fund Exercise

We’ve seen 3 institutional traders add shares of $MOLN stock to their portfolio, and 4 lower their positions of their most up-to-date quarter.

Listed here are some of the biggest latest strikes:

• SUVRETTA CAPITAL MANAGEMENT, LLC added 1,821,494 shares (+455.4%) to their portfolio in This autumn 2024, for an estimated $8,648,453
• BVF INC/IL added 910,747 shares (+205.5%) to their portfolio in This autumn 2024, for an estimated $4,324,226
• OLD MISSION CAPITAL LLC eliminated 10,365 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $52,727
• TANG CAPITAL MANAGEMENT LLC eliminated 2,500 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $12,717
• UBS GROUP AG added 1,626 shares (+31.0%) to their portfolio in This autumn 2024, for an estimated $7,720
• MORGAN STANLEY eliminated 133 shares (-26.6%) from their portfolio in This autumn 2024, for an estimated $631
• QUBE RESEARCH & TECHNOLOGIES LTD eliminated 16 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $81

To trace hedge funds’ stock portfolios, try Quiver Quantitative’s institutional holdings dashboard.

Full Launch

• Participation in hearth chats at TD Cowen and Leerink healthcare conferences
• Name on 2024 financial outcomes on March 7 at 2.00 pm CET (8.00 am ET)

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) —

Molecular Companions

AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein medicine often called DARPin therapeutics (“Molecular Partners” or the “Company”), as we speak introduced its attendance and shows at upcoming investor conferences.

Molecular Companions may even host a convention call on March 7 on its full-year 2024 financial report. The Annual Report is because of be revealed March 6.

Particulars of the occasions:

TD Cowen forty fourth Annual Well being Care Convention

Boston, MA, March 3-5, 2025

Molecular Companions CEO Patrick Amstutz and CMO Dr. Philippe Legenne will participate in a hearth chat on Monday, March 3 at 9.10 am ET (3.10 pm CET).

Full 12 months 2024 Monetary Outcomes Convention Name

Friday, March 7, 2025 at 8.00 am ET (2.00 pm CET).

To register for the complete 12 months 2024 convention call, please dial the next numbers roughly 10 minutes earlier than the beginning of the presentation:

A replay will likely be made accessible on the Firm’s web site underneath the investor part.

Leerink Companions International Healthcare Convention 2025

Miami, FL, March 10-12 March, 2025

Molecular Companions CEO Patrick Amstutz and CMO Dr. Philippe Legenne will participate in a hearth chat on Monday, March 10 at 10.40 am ET (3.40 pm CET).

About Molecular Companions AG

Molecular Companions AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges different drug modalities can not readily handle. The Firm has applications in numerous levels of pre-clinical and medical development, with oncology as its principal focus. Molecular Companions leverages the benefits of DARPins to offer distinctive options to sufferers by way of its proprietary applications in addition to by way of partnerships with main pharmaceutical firms. Molecular Companions was based in 2004 and has places of work in each Zurich, Switzerland and Harmony, MA, USA. For more data, go to

www.molecularpartners.com

and discover us on LinkedIn and Twitter/X

@MolecularPrtnrs

For additional particulars, please contact:

Seth Lewis, SVP Investor Relations & Technique

Harmony, Massachusetts, U.S.

[email protected]

Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Administration & Communications

Zurich-Schlieren, Switzerland

[email protected]

Tel: +41 44 575 19 35

Cautionary Be aware Concerning Ahead-Wanting Statements

Any statements contained on this press release that don’t describe historic details could represent forward-looking statements as that time period is outlined within the Non-public Securities Litigation Reform Act of 1995, as amended, together with, with out limitation: implied and specific statements concerning the medical development of Molecular Companions’ present or future product candidates; expectations concerning timing for reporting knowledge from ongoing medical trials or the initiation of future medical trials; the potential therapeutic and medical advantages of Molecular Companions’ product candidates and its RDT and Change-DARPin platforms; the choice and development of future applications; Molecular Companions’ collaboration with Orano Med together with the advantages and outcomes which may be achieved by way of the collaboration; and Molecular Companions’ anticipated business and financial outlook, together with anticipated bills and money utilization for 2024 and its expectation of its present money runway. These statements could also be recognized by phrases akin to “aim”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and comparable expressions, and are primarily based on Molecular Companions’ present beliefs and expectations. These statements contain dangers and uncertainties that would trigger precise outcomes to vary materially from these mirrored in such statements. Some of the important thing elements that would trigger precise outcomes to vary from Molecular Companions’ expectations embody its plans to develop and probably commercialize its product candidates; Molecular Companions’ reliance on third social gathering companions and collaborators over which it could not all the time have full control; Molecular Companions’ ongoing and deliberate medical trials and preclinical research for its product candidates, together with the timing of such trials and research; the risk that the outcomes of preclinical research and medical trials will not be predictive of future leads to reference to future medical trials; the timing of and Molecular Companions’ skill to acquire and preserve regulatory approvals for its product candidates; the extent of medical trials probably required for Molecular Companions’ product candidates; the medical utility and talent to attain market acceptance of Molecular Companions’ product candidates; the potential that Molecular Companions’ product candidates could exhibit critical adversarial, undesirable or unacceptable negative effects; the impression of any health pandemic, macroeconomic elements and different world occasions on Molecular Companions’ preclinical research, medical trials or operations, or the operations of third events on which it depends; Molecular Companions’ plans and development of any new indications for its product candidates; Molecular Companions’ commercialization, advertising and manufacturing capabilities and strategy; Molecular Companions’ mental property place; Molecular Companions’ skill to determine and in-license extra product candidates; unanticipated elements along with the foregoing which will impression Molecular Companions’ financial and business projections and steering; and different dangers and uncertainties which might be described within the Danger Elements part of Molecular Companions’ Annual Report on Type 20-F for the fiscal 12 months ended December 31, 2023, filed with Securities and Change Fee (SEC) on March 14, 2024 and different filings Molecular Companions makes with the SEC. These paperwork can be found on the Buyers web page of Molecular Companions’ web site at www.molecularpartners.com. As well as, this press release comprises data referring to interim knowledge as of the related knowledge cutoff date, outcomes of which can differ from topline outcomes which may be obtained sooner or later. Any forward-looking statements communicate solely as of the date of this press release and are primarily based on data accessible to Molecular Companions as of the date of this release, and Molecular Companions assumes no obligation to, and doesn’t intend to, replace any forward-looking statements, whether or not as a outcome of new data, future occasions or in any other case.

This text was initially revealed on Quiver Information, learn the complete story.

The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.